We have just wrapped up our first exhibition at the American Diabetes Association (ADA) meeting in Chicago – which was a great experience and showed us that there is more opportunity to expand the reach of EECP® Therapy than ever before!
The show lasted from June 21st through 25th and was well attended with approximately 14,000 attendees from across the United States and around the world. The Vasomedical booth had a steady flow of interested attendees, and we spent a great deal of time educating attendees about EECP Therapy and the benefits it can have for patients.
The people we spoke with were fascinated to learn that EECP Therapy can provide relief to patients with angina symptoms such as chest or atypical pain, shortness of breath and fatigue, among others. This event was so relevant to our business because many patients with diabetes also have ischemic heart disease and can experience angina symptoms despite being on maximal medication. To our delight, numerous attendees commented that when they return home they are planning to speak to their cardiologists and hospitals about the positive effects EECP Therapy can have on their patients.
The attendees were interested to learn more about the clinical evidence recently published by the researchers at the University of Florida in Gainesville demonstrating the positive effects of EECP Therapy on glucose tolerance and insulin resistance.
At the exhibition, we also saw a great deal of interest in our BIOX ECG Holters and ambulatory blood pressure monitors as well as our EZ® pulse oximeters.
We thought the ADA was a successful conference, as we were able to raise awareness for EECP Therapy in this new patient population. We are continuing to learn more about diabetic patients and the potential impact EECP Therapy can have on this patient group’s quality of life. We hope by next year’s ADA we have even more insight to share!
Next stop: Amsterdam, Netherlands!